Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Akouos, Inc. today announced that it has entered into a definitive agreement to be acquired by Eli Lilly and Company. Under the terms of the agreement, Lilly…
Eli Lilly said on Tuesday it would acquire Akouos in a deal valued at up to $610 million including milestones, expanding its presence in gene therapy with…
Phase 1/2 AK-OTOF-101 study of AAVAnc80-hOTOF (AK-OTOF / LY3884961) for OTOF-mediated sensorineural hearing loss. Overall status RECRUITING; record last…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Lilly acquired Akouos for $12.50/share cash (~$487M) plus a CVR up to $3.00/share, total potential deal value ~$610M. The acquisition added Akouos's portfolio of AAV gene therapies for inner-ear conditions, with lead asset AK-OTOF for OTOF-mediated hearing loss. Closed December 1, 2022.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Akouos Inc. (this deal) | 2022 | $610M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2022 deals · Eli Lilly and Company deals · Gene Therapy deals